| 1 -0.03 (-2.91%) | 07-26 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.21 | 1-year : | 1.41 |
| Resists | First : | 1.04 | Second : | 1.21 |
| Pivot price | 1 | |||
| Supports | First : | 0.99 | Second : | 0.95 |
| MAs | MA(5) : | 1 | MA(20) : | 1 |
| MA(100) : | 1.01  |
MA(250) : | 1.45 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.2 | D(3) : | 50.2 |
| RSI | RSI(14): 57.3 | |||
| 52-week | High : | 2.76 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PSTI ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.04 - 1.05 | 1.05 - 1.05 |
| Low: | 0.95 - 0.95 | 0.95 - 0.96 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Mon, 25 Jul 2022
Pluristem Therapeutics Inc. Changes its Name to “Pluri - GlobeNewswire
Wed, 10 Nov 2021
Pluristem Receives Approval for Grant from the Israel - GlobeNewswire
Tue, 31 Jul 2018
Pluristem Therapeutics Inc. (NASDAQ:PSTI) has coverage initiated with a Buy rating and $4.50 price target - marketexclusive.com
Thu, 19 Oct 2017
FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome - BioInformant
Mon, 16 Sep 2013
Pluristem: FDA Lifts Clinical Hold On Phase II Intermittent Claudication Study - RTTNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 2.759e+007 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 487 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.605e+007 |
| EPS Est Next Qtrly | -0.1 |
| EPS Est This Year | -0.35 |
| EPS Est Next Year | -0.35 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -20 % |
| Return on Assets (ttm) | 212.8 % |
| Return on Equity (ttm) | -37.4 % |
| Qtrly Rev. Growth | 234000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -45.32 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 1.2 |
| Dividend | 0 |
| Forward Dividend | 391400 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-07-24 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|